Eli Lilly (LLY) announced that the Medicines and Healthcare products Regulatory Agency, or MHRA, has granted marketing authorization for donanemab, an injection for intravenous infusion every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer’s disease in eligible adults in Great Britain. Eligible patients are limited to apolipoprotein E e4, or ApoE e4, heterozygotes or non-carriers, which is a requirement for the class of currently approved amyloid-targeting therapies in Great Britain. Donanemab is the only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed. Great Britain is the third major market to approve donanemab, marketed as Kisunla.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- GE Aerospace, GM report quarterly earnings beats: Morning Buzz
- Pfizer, Lilly pressed about telehealth prescriber relationships, STAT reports
- Mangoceuticals ‘refutes’ claims by Eli Lilly regarding sale of tirzepatide
- Morgan Stanley names Amgen ‘catalyst-driven idea’ into Phase 2 MariTide data
- Eli Lilly (NYSE:LLY) Sues Vendors over Copycat Weight Loss Products